BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int 2012;82:235-41. [PMID: 22437411 DOI: 10.1038/ki.2012.76] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Fishbane S, Wish JB. A physician's perseverance uncovers problems in a key nephrology study. Kidney Int 2012;82:135-7. [PMID: 22743565 DOI: 10.1038/ki.2012.122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
2 Fernandez H, Singh AK. Management of Anemia in Chronic Kidney Disease. Chronic Renal Disease. Elsevier; 2015. pp. 624-33. [DOI: 10.1016/b978-0-12-411602-3.00051-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Birnie K, Caskey F, Ben-Shlomo Y, Sterne JA, Gilg J, Nitsch D, Tomson C. Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13. Nephrol Dial Transplant 2017;32:692-8. [PMID: 27190350 DOI: 10.1093/ndt/gfw043] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, Zeig S, Negoi DG, Hiremath AN, Blumenthal SS, Sika M, Niecestro R, Koury MJ, Ma KN, Greene T, Lewis JB, Dwyer JP; Collaborative Study Group. Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. J Am Soc Nephrol 2015;26:2578-87. [PMID: 25736045 DOI: 10.1681/ASN.2014080842] [Cited by in Crossref: 66] [Cited by in F6Publishing: 28] [Article Influence: 9.4] [Reference Citation Analysis]
5 Patel SS. Treating pain to improve quality of life in end-stage renal disease. Semin Dial 2013;26:268-73. [PMID: 23432440 DOI: 10.1111/sdi.12066] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
6 Warady BA, Silverstein DM. Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease. Pediatr Nephrol 2014;29:1493-505. [PMID: 24005791 DOI: 10.1007/s00467-013-2557-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Shakeri H, Arman F, Hossieni M, Omrani HR, Vahdani A, Shakeri J. Depression, Anxiety and Disease-Related Variables and Quality of Life Among Individuals With Systemic Lupus Erythematosus Living in Kermanshah Province, Iran. Iran Red Crescent Med J 2015;17:e31047. [PMID: 26756021 DOI: 10.5812/ircmj.31047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
8 Kwon O, Jang HM, Jung HY, Kim YS, Kang SW, Yang CW, Kim NH, Choi JY, Cho JH, Kim CD, Kim YL, Park SH; Clinical Research Center for End-Stage Renal Disease (CRC- ESRD) Investigators. The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients. PLoS One 2015;10:e0140241. [PMID: 26452232 DOI: 10.1371/journal.pone.0140241] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
9 Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, Szczech L. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis 2013;62:849-59. [PMID: 23891356 DOI: 10.1053/j.ajkd.2013.06.008] [Cited by in Crossref: 131] [Cited by in F6Publishing: 101] [Article Influence: 14.6] [Reference Citation Analysis]
10 Locatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, Hörl W, London G, Vanholder R, Van Biesen W; ERA-EDTA ERBP Advisory Board. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013;28:1346-59. [PMID: 23585588 DOI: 10.1093/ndt/gft033] [Cited by in Crossref: 210] [Cited by in F6Publishing: 176] [Article Influence: 23.3] [Reference Citation Analysis]
11 Schooling CM, Xu L, Zhao J, Au Yeung SL. Norms hide causes-the example of testosterone. Int J Epidemiol 2014;43:1987-8. [PMID: 25183747 DOI: 10.1093/ije/dyu185] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Guedes M, Guetter CR, Erbano LHO, Palone AG, Zee J, Robinson BM, Pisoni R, de Moraes TP, Pecoits-Filho R, Baena CP. Physical health-related quality of life at higher achieved hemoglobin levels among chronic kidney disease patients: a systematic review and meta-analysis. BMC Nephrol 2020;21:259. [PMID: 32641153 DOI: 10.1186/s12882-020-01912-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Lopes JM, Fukushima RLM, Inouye K, Pavarini SCI, Orlandi FDS. Qualidade de vida relacionada à saúde de pacientes renais crônicos em diálise. Acta paul enferm 2014;27:230-6. [DOI: 10.1590/1982-0194201400039] [Cited by in Crossref: 10] [Article Influence: 1.3] [Reference Citation Analysis]
14 Bazeley J, Wish JB. The Evolution of Target Hemoglobin Levels in Anemia of Chronic Kidney Disease. Adv Chronic Kidney Dis 2019;26:229-36. [PMID: 31477253 DOI: 10.1053/j.ackd.2019.06.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Doshi P, Jefferson T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open 2013;3:e002496. [PMID: 23447465 DOI: 10.1136/bmjopen-2012-002496] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
16 Zhong Y, Jiang CQ, Cheng KK, Zhang WS, Liu B, Jin YL, Lam TH, Leung GM, Schooling CM. Height, its components, and coagulability among older Chinese: the Guangzhou biobank cohort study. Am J Hum Biol 2014;26:603-8. [PMID: 24909113 DOI: 10.1002/ajhb.22568] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Schooling CM, Xu L, Zhao J. Debate: Testosterone Therapy Reduces Cardiovascular Risk in Men with Diabetes. Against the Motion. Curr Cardiovasc Risk Rep 2015;9. [DOI: 10.1007/s12170-015-0449-2] [Reference Citation Analysis]
18 McMahon GM, Singh AK. Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease. Curr Opin Nephrol Hypertens 2019;28:600-6. [PMID: 31567284 DOI: 10.1097/MNH.0000000000000554] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
19 Coyne DW, Goldsmith D, Macdougall IC. New options for the anemia of chronic kidney disease. Kidney Int Suppl (2011) 2017;7:157-63. [PMID: 30675430 DOI: 10.1016/j.kisu.2017.09.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
20 Coyne DW. PIVOTAL trial: iron loading improves clinical outcomes. Nat Rev Nephrol 2019;15:260-1. [DOI: 10.1038/s41581-019-0128-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Shah B, Jagtap P, Sarmah D, Datta A, Raut S, Sarkar A, Bohra M, Singh U, Baidya F, Kalia K, Borah A, Dave KR, Yavagal DR, Bhattacharya P. Cerebro-renal interaction and stroke. Eur J Neurosci 2021;53:1279-99. [PMID: 32979852 DOI: 10.1111/ejn.14983] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
22 Ghanta M, Kozicky M, Jim B. Pathophysiologic and treatment strategies for cardiovascular disease in end-stage renal disease and kidney transplantations. Cardiol Rev. 2014;23:109-118. [PMID: 25420053 DOI: 10.1097/crd.0000000000000044] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
23 Besarab A, Bolton WK, Nissenson AR, Schwab SJ. The normal HCT trial re-revisited: what were the actual findings? Kidney International 2012;82:242. [DOI: 10.1038/ki.2012.204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
24 Freburger JK, Ellis AR, Wang L, Butler AM, Kshirsagar AV, Winkelmayer WC, Brookhart MA. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis. American Journal of Kidney Diseases 2016;67:271-82. [DOI: 10.1053/j.ajkd.2015.09.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
25 Garattini S, Perico N. Drug development: how academia, industry and authorities interact. Nat Rev Nephrol 2014;10:602-10. [PMID: 25092151 DOI: 10.1038/nrneph.2014.133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Fuller DS, Bieber BA, Pisoni RL, Li Y, Morgenstern H, Akizawa T, Jacobson SH, Locatelli F, Port FK, Robinson BM. International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol 2016;27:2205-15. [PMID: 26582402 DOI: 10.1681/ASN.2015060673] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
27 Wish JB. Perspective: Will We Ever Know the Optimal Hgb Level in ESRD? J Am Soc Nephrol 2018;29:2454-7. [PMID: 30185470 DOI: 10.1681/ASN.2018040363] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
28 Allon M. Evidence-based cardiology in hemodialysis patients. J Am Soc Nephrol 2013;24:1934-43. [PMID: 24136920 DOI: 10.1681/ASN.2013060632] [Cited by in Crossref: 32] [Cited by in F6Publishing: 7] [Article Influence: 3.6] [Reference Citation Analysis]
29 Zhong Y, Jiang C, Cheng KK, Zhang W, Jin Y, Lam TH, Woo J, Leung GM, Schooling CM. Environment-wide association study to identify factors associated with hematocrit: evidence from the Guangzhou Biobank Cohort Study. Ann Epidemiol 2016;26:638-642.e2. [PMID: 27502758 DOI: 10.1016/j.annepidem.2016.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
30 Hahn D, Cody JD, Hodson EM. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients. Cochrane Database Syst Rev 2014;:CD003895. [PMID: 24872328 DOI: 10.1002/14651858.CD003895.pub3] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
31 Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S; Dialysis Advisory Group of the American Society of Nephrology. Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol 2015;26:1238-47. [PMID: 25542967 DOI: 10.1681/ASN.2014090922] [Cited by in Crossref: 56] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
32 Jefferson T, Doshi P, Boutron I, Golder S, Heneghan C, Hodkinson A, Jones M, Lefebvre C, Stewart LA. When to include clinical study reports and regulatory documents in systematic reviews. BMJ Evid Based Med 2018;23:210-7. [PMID: 30309870 DOI: 10.1136/bmjebm-2018-110963] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
33 Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ. 2013;346:f2865. [PMID: 23766480 DOI: 10.1136/bmj.f2865] [Cited by in Crossref: 91] [Cited by in F6Publishing: 66] [Article Influence: 10.1] [Reference Citation Analysis]
34 Keller F, Marczewski K, Pavlović D. The relationship between the physician and pharmaceutical industry: background ethics and regulation proposals. Croat Med J 2016;57:398-401. [PMID: 27586556 DOI: 10.3325/cmj.2016.57.398] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
35 Song HY, Wei CM, Zhou WX, Hu HF, Wan QJ. Association between admission hemoglobin level and prognosis in patients with type 2 diabetes mellitus. World J Diabetes 2021; 12(11): 1917-1927 [PMID: 34888016 DOI: 10.4239/wjd.v12.i11.1917] [Reference Citation Analysis]
36 Biggar P, Kim GH. Treatment of renal anemia: Erythropoiesis stimulating agents and beyond. Kidney Res Clin Pract 2017;36:209-23. [PMID: 28904872 DOI: 10.23876/j.krcp.2017.36.3.209] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
37 Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis 2019;73:309-15. [PMID: 30578152 DOI: 10.1053/j.ajkd.2018.10.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
38 Doan KVD, Nguyen HTM, Nguyen NTH, Dang KC, Yang SH, Duong TV. Associations of Socio-Demographic, Clinical and Biochemical Parameters with Healthcare Cost, Health- and Renal-Related Quality of Life in Hemodialysis Patients: A Clinical Observational Study. Int J Environ Res Public Health 2020;17:E6552. [PMID: 32916843 DOI: 10.3390/ijerph17186552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Singh AK, Fishbane SN. How Can Erythropoeitin-Stimulating Agent Use be Reduced in Chronic Dialysis Patients?: The Itsy Bitsy Anemia Problem. Semin Dial 2013;26:531-4. [DOI: 10.1111/sdi.12104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
40 Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010590. [PMID: 25486075 DOI: 10.1002/14651858.CD010590.pub2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
41 Fishbane S, Coyne DW. How I treat renal anemia. Blood 2020;136:783-9. [PMID: 32556307 DOI: 10.1182/blood.2019004330] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Herrington W, Haynes R, Staplin N, Emberson J, Baigent C, Landray M. Evidence for the prevention and treatment of stroke in dialysis patients. Semin Dial 2015;28:35-47. [PMID: 25040468 DOI: 10.1111/sdi.12281] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
43 Toida T, Iwakiri T, Sato Y, Komatsu H, Kitamura K, Fujimoto S. Relationship between Hemoglobin Levels Corrected by Interdialytic Weight Gain and Mortality in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study. PLoS One 2017;12:e0169117. [PMID: 28046068 DOI: 10.1371/journal.pone.0169117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
44 Shreay S, Ma M, McCluskey J, Mittelhammer RC, Gitlin M, Stephens JM. Efficiency of U.S. dialysis centers: an updated examination of facility characteristics that influence production of dialysis treatments. Health Serv Res 2014;49:838-57. [PMID: 24237043 DOI: 10.1111/1475-6773.12127] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
45 Yamamoto H, Nishi S, Tomo T, Masakane I, Saito K, Nangaku M, Hattori M, Suzuki T, Morita S, Ashida A, Ito Y, Kuragano T, Komatsu Y, Sakai K, Tsubakihara Y, Tsuruya K, Hayashi T, Hirakata H, Honda H. 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. Ren Replace Ther 2017;3. [DOI: 10.1186/s41100-017-0114-y] [Cited by in Crossref: 81] [Cited by in F6Publishing: 20] [Article Influence: 16.2] [Reference Citation Analysis]
46 Zhong Y, Lin S, Schooling C. The effect of hematocrit and hemoglobin on the risk of ischemic heart disease: A Mendelian randomization study. Preventive Medicine 2016;91:351-5. [DOI: 10.1016/j.ypmed.2016.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
47 Preziosi P. Faster drug approval: challenges for safety. Expert Opin Drug Saf 2016;15:1205-18. [PMID: 27308948 DOI: 10.1080/14740338.2016.1194825] [Reference Citation Analysis]
48 Luo S, Au Yeung SL, Zuber V, Burgess S, Schooling CM. Impact of Genetically Predicted Red Blood Cell Traits on Venous Thromboembolism: Multivariable Mendelian Randomization Study Using UK Biobank. J Am Heart Assoc 2020;9:e016771. [PMID: 32635790 DOI: 10.1161/JAHA.120.016771] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
49 Hörl WH. Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol 2013;9:291-301. [PMID: 23438972 DOI: 10.1038/nrneph.2013.21] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
50 Coyne DW. The KDOQI US commentary on KDIGO anemia guideline and quality of life. Am J Kidney Dis 2014;63:540. [PMID: 24560158 DOI: 10.1053/j.ajkd.2013.08.037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
51 Rognoni C, Ortalda V, Biasi C, Gambaro G. Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy. Adv Ther 2019;36:3253-64. [PMID: 31489572 DOI: 10.1007/s12325-019-01089-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
52 Barbieri C, Bolzoni E, Mari F, Cattinelli I, Bellocchio F, Martin JD, Amato C, Stopper A, Gatti E, Macdougall IC, Stuard S, Canaud B. Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients. PLoS One 2016;11:e0148938. [PMID: 26939055 DOI: 10.1371/journal.pone.0148938] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
53 Coronado Daza J, Martí-Carvajal AJ, Ariza García A, Rodelo Ceballos J, Yomayusa González N, Páez-Canro C, Loza Munárriz C, Urrútia G. Early versus delayed erythropoietin for the anaemia of end-stage kidney disease. Cochrane Database Syst Rev 2015;:CD011122. [PMID: 26671531 DOI: 10.1002/14651858.CD011122.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
54 Silver SA, Alaryni A, Alghamdi A, Digby G, Wald R, Iliescu E. Routine Laboratory Testing Every 4 Versus Every 6 Weeks for Patients on Maintenance Hemodialysis: A Quality Improvement Project. Am J Kidney Dis 2019;73:496-503. [PMID: 30598347 DOI: 10.1053/j.ajkd.2018.10.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
55 Jefferson T. Sponsorship bias in clinical trials: growing menace or dawning realisation? J R Soc Med 2020;113:148-57. [PMID: 32286115 DOI: 10.1177/0141076820914242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]